The novel <scp>PAR</scp>2 ligand <scp>C</scp>391 blocks multiple <scp>PAR</scp>2 signalling pathways <i>in vitro</i> and <i>in vivo</i>

Scott Boitano, Justin Hoffman, Andrea N. Flynn, Marina N. Asiedu, Dipti V. Tillu, Zhenyu Zhang, Cara L. Sherwood, Candy Rivas, Kathryn DeFea, Josef Vágner,

British Journal of Pharmacology · 2015 · 39 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

Background and Purpose Proteinase‐activated receptor‐2 ( PAR 2) is a GPCR linked to diverse pathologies, including acute and chronic pain. PAR 2 is one of the four PARs that are activated by proteolytic cleavage of the extracellular amino terminus, resulting in an exposed, tethered peptide agonist. Several peptide and peptidomimetic agonists, with high potency and efficacy, have been developed to probe the functions of PAR 2, in vitro and in vivo . However, few similarly potent and effective antagonists have been described. Experimental Approach We modified the peptidomimetic PAR 2 agonist, 2‐furoyl‐ LIGRLO ‐ NH 2 , to create a novel PAR 2 peptidomimetic ligand, C 391. C 391 was evaluated for PAR 2 agonist/antagonist activity to PAR 2 across G q signalling pathways using the naturally expressing PAR 2 cell line 16 HBE 14o‐. For antagonist studies, a highly potent and specific peptidomimetic agonist (2‐aminothiazo‐4‐yl‐ LIGRL ‐ NH 2 ) and proteinase agonist (trypsin) were used to activate PAR 2. C391 was also evaluated in vivo for reduction of thermal hyperalgesia, mediated by mast cell degranulation, in mice. Key Results C391 is a potent and specific peptidomimetic antagonist, blocking multiple signalling pathways ( G q ‐dependent Ca 2+ , MAPK ) induced following peptidomimetic or proteinase activation of human PAR 2. In a PAR 2‐dependent behavioural assay in mice, C 391 dose‐dependently (75 μg maximum effect) blocked the thermal hyperalgesia, mediated by mast cell degranulation. Conclusions and Implications C391 is the first low MW antagonist to block both PAR 2 Ca 2+ and MAPK signalling pathways activated by peptidomimetics and/or proteinase activation. C391 represents a new molecular structure for PAR 2 antagonism and can serve as a basis for further development for this important therapeutic target.

References

36